ArticleInfectious Disease Modelling2026
Impact of the first booster vaccine against SARS-CoV-2 in Chile.
Article in Infectious Disease Modelling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present paper proposes a novel methodology for evaluating the impact of a vaccination plan against a transmissible disease. The methodology has two distinct stages. The initial stage comprises a compartmental model that describes the transmission of the disease within the population. This model is composed of fundamental parts representing the vaccination status and is used in this initial stage to estimate the number of cases and deaths averted by the vaccination plan. The case dynamics generated by the compartmental model serve as the input for a data-driven model in the second part of the methodology. The second model is statistical in nature and provides additional information regarding the number of hospitalizations and ICU admissions averted. This methodology is applied to assess the impact of booster SARS-CoV-2 vaccines in Chile, resulting in an estimation of 84 % (95 % confidence interval (CI): 74 %-92 %) of cases, 73 % (95 % CI: 57 %, 80 %) of hospital admissions, 77 % (95 % CI: 61 %, 84 %) of intensive care unit admissions, and 78 % (95 % CI: 62 %-85 %) of deaths averted between August 16 and December 31, 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.